A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1
F. D. Johnson, J. Ferrarone, A. Liu, C. Brandstadter, R. Munuganti, D. Fansworth, D. Lu, J. Luu, T. Sihota, S. Jansen, A. Nagelberg, R. Shi, G. C. Forcina, X. ZhangiD, G. S. W. Cheng, S. E. Spencer Miko, G. de Rappard-Yuswack, P. H. Sorenesen, S. J. Dixon, U. Guha, K. Becker, H. Djaballah, R. Somwar, H. Varmus, G. B. Morin, W. W. Lockwood
Abstract
High-throughput phenotype-based screening of large libraries of novel compounds without known targets can identify small molecules that elicit a desired cellular response, but additional approaches are required to find and characterize their targets and mechanisms of action. Here we show that a compound termed lung cancer screen 3 (LCS3), previously selected for its ability to impair the growth of human lung adenocarcinoma (LUAD) cell lines, but not normal lung cells, induces oxidative stress and activates the NRF2 signaling pathway by generating reactive oxygen species (ROS) in sensitive LUAD cell lines. To identify the target that mediates this effect, we applied thermal proteome profiling (TPP) and uncovered the disulfide reductases GSR and TXNRD1 as LCS3 targets. Through enzymatic assays using purified protein, we confirmed that LCS3 inhibits disulfide reductase activity through a reversible, uncompetitive mechanism. Further, we demonstrate that LCS3-sensitive LUAD cells are correspondingly sensitive to the synergistic inhibition of glutathione and thioredoxin pathways. Lastly, a genome-wide CRISPR knockout screen identified the loss of NQO1 as a mechanism of LCS3 resistance. This work highlights the ability of TPP to uncover targets of small molecules identified by high-throughput screens and demonstrates the potential utility of inhibiting disulfide reductases as a therapeutic strategy for LUAD.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer
C. Jiang, N. P. Ward, … G. M. DeNicola·bioRxiv·Mar 8, 2022
- Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers
Cristina Andreani, Caterina Bartolacci, … Pier Paolo Scaglioni·bioRxiv·Jul 25, 2025
- Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy
Jana Samarin, Hana Nůsková, … Nikolas Gunkel·Nature CommunicationsPeer-reviewed·Apr 11, 2026
- Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes.
K. Davidson, P. Grevitt, … T. V. Sharp·bioRxiv·Feb 1, 2021
- NRF2 activation induces NADH-reductive stress providing a metabolic vulnerability in lung cancer
Tommy Weiss‐Sadan, Maolin Ge, … Liron Bar‐Peled·Cell MetabolismPeer-reviewed·Feb 24, 2023
- SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer
Shinji Nakamichi, Natalia von Muhlinen, … Curtis C. Harris·CarcinogenesisPeer-reviewed·Oct 1, 2025